<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311362</url>
  </required_header>
  <id_info>
    <org_study_id>K331</org_study_id>
    <secondary_id>2010-022868-13</secondary_id>
    <nct_id>NCT01311362</nct_id>
  </id_info>
  <brief_title>Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan</brief_title>
  <official_title>Influence of CYP3A4-induction by St. John's Wort (SJW) on the Steady State Pharmacokinetics of Ambrisentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerd Mikus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess the impact of CYP3A4-induction by SJW on steady&#xD;
      state ambrisentan and the impact of the cytochrome P450 2C19 (CYP2C19) genotype (*2 and *3&#xD;
      allele vs. wild type; ~2-5% poor metabolisers in Caucasian population) on the&#xD;
      pharmacokinetics of ambrisentan in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of Ambrisentan</measure>
    <time_frame>after first dose, at steady-state, during St John's wort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Ambrisentan</measure>
    <time_frame>after first dose, at steady-state and during St John's wort</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Drug Interactions</condition>
  <arm_group>
    <arm_group_label>CYP2C19 wild type</arm_group_label>
    <description>CYP2C19 wild type =&quot;extensive metaboliser&quot;&#xD;
Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20&#xD;
Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2C19 mutant</arm_group_label>
    <description>CYP2C19 *2/*2 or *2/*3 or *3/*3 = &quot;poor metaboliser&quot;&#xD;
Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20&#xD;
Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. Johns wort</intervention_name>
    <description>Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20&#xD;
Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20</description>
    <arm_group_label>CYP2C19 mutant</arm_group_label>
    <arm_group_label>CYP2C19 wild type</arm_group_label>
    <other_name>Jarsin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good state of health (physically and mentally)&#xD;
&#xD;
          -  Able to communicate well with the investigator, to understand and comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  Voluntarily signed informed consent after full explanation of the study to the&#xD;
             participant.&#xD;
&#xD;
          -  No clinically relevant findings in any of the investigations of the pre-study&#xD;
             examination, especially aminotransferase elevations ≥ 3 × upper limit of normal (ULN).&#xD;
             Minor deviations of other laboratory values from normal range may be acceptable, if&#xD;
             judged by the investigator to be of no clinical relevance.&#xD;
&#xD;
          -  Known genotype for CYP2C19 polymorphism.&#xD;
&#xD;
          -  Agreement to abstain from alcoholic beverages during the time of the study.&#xD;
&#xD;
          -  Females must agree to use a reliable contraception (Pearl Index &lt;1%), e.g. double&#xD;
             barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any regular drug treatment within the last two months, except for oral contraceptives&#xD;
             in female volunteers and L-thyroxine.&#xD;
&#xD;
          -  Any intake of a substance known to induce or inhibit drug metabolising enzymes or drug&#xD;
             transporters within a period of less than 10 times the respective elimination&#xD;
             half-life or 2 weeks, whatever is longer&#xD;
&#xD;
          -  Any participation in a clinical trial within the last month before inclusion&#xD;
&#xD;
          -  Any physical disorder which could interfere with the participant's safety during the&#xD;
             clinical trial or with the study objectives&#xD;
&#xD;
          -  Any acute or chronic illness, or clinically relevant findings in the pre-study&#xD;
             examination, especially: a) any condition, which could modify absorption,&#xD;
             distribution, metabolism, or excretion of the drug regimen under investigation b)&#xD;
             Allergies (except for mild forms of hay fever) or history of hypersensitivity&#xD;
             reactions&#xD;
&#xD;
          -  Regular smoking&#xD;
&#xD;
          -  Blood donation within 6 weeks before first study day&#xD;
&#xD;
          -  Excessive alcohol drinking (more than approximately 20 g alcohol per day)&#xD;
&#xD;
          -  Inability to communicate well with the investigator due to language problems or poor&#xD;
             mental development&#xD;
&#xD;
          -  Inability or unwillingness to give written informed consent&#xD;
&#xD;
          -  Known or planned pregnancy or breast feeding&#xD;
&#xD;
          -  Pre-existing moderate or severe liver impairment&#xD;
&#xD;
          -  Contraindication against midazolam, ambrisentan, or SJW or any known intolerance to&#xD;
             any of these substances or their additives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Mikus, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>deputy head of department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20. doi: 10.1038/clpt.2010.120. Epub 2010 Sep 1.</citation>
    <PMID>20811346</PMID>
  </reference>
  <reference>
    <citation>Harrison B, Magee MH, Mandagere A, Walker G, Dufton C, Henderson LS, Boinpally R. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig. 2010;30(12):875-885. doi: 10.2165/11539110-000000000-00000.</citation>
    <PMID>20923245</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>July 9, 2014</results_first_submitted>
  <results_first_submitted_qc>May 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2015</results_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Gerd Mikus</investigator_full_name>
    <investigator_title>Head of Clinical Research Unit</investigator_title>
  </responsible_party>
  <keyword>Steady-state</keyword>
  <keyword>Ambrisentan</keyword>
  <keyword>St. Johns Wort</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan After First Dose</title>
          <description>administration of ambrisentan 5 mg p.o. single dose administration of ambrisentan 5 mg p.o. q.d. on day 3-10 administration of ambrisentan 5 mg p.o. q.d on day 11-20 and administration of SJW 300 mg p.o. t.i.d. on day 11-20</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Ambrisentan Single Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">All 20 study participants completed each study period. Total number of study participants: 20</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Ambrisentan Steady-state</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Ambrisentan and SJW</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ambrisentan</title>
          <description>administration of ambrisentan 5 mg p.o. single dose administration of ambrisentan 5 mg p.o. q.d. on day 3-10 administration of ambrisentan 5 mg p.o. q.d on day 11-20 and administration of SJW 300 mg p.o. t.i.d. on day 11-20</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC of Ambrisentan</title>
        <time_frame>after first dose, at steady-state, during St John's wort</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan After First Dose</title>
            <description>administration of ambrisentan 5 mg p.o. single dose</description>
          </group>
          <group group_id="O2">
            <title>Ambrisentan at Steady-state</title>
            <description>administration of ambrisentan 5 mg p.o. q.d. on day 3-10</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan During St John's Wort</title>
            <description>administration of ambrisentan 5 mg p.o. q.d. on day 11-20 and administration of SJW 300 mg t.i.d. on day 11-20</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Ambrisentan</title>
          <units>h*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3670" lower_limit="3200" upper_limit="4220"/>
                    <measurement group_id="O2" value="3520" lower_limit="3120" upper_limit="3970"/>
                    <measurement group_id="O3" value="2790" lower_limit="2470" upper_limit="3150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Ambrisentan</title>
        <time_frame>after first dose, at steady-state and during St John's wort</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan After First Dose</title>
            <description>administration of ambrisentan 5 mg p.o. single dose</description>
          </group>
          <group group_id="O2">
            <title>Ambrisentan at Steady-state</title>
            <description>administration of ambrisentan 5 mg p.o. q.d. on day 3-10</description>
          </group>
          <group group_id="O3">
            <title>Ambrisentan During St John's Wort</title>
            <description>administration of ambrisentan 5 mg p.o. q.d. on day 11-20 and administration of SJW 300 mg p.o. t.i.d. on day 11-20</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Ambrisentan</title>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447" lower_limit="397" upper_limit="502"/>
                    <measurement group_id="O2" value="456" lower_limit="399" upper_limit="521"/>
                    <measurement group_id="O3" value="383" lower_limit="331" upper_limit="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ambrisentan After First Dose</title>
          <description>administration of ambrisentan 5 mg p.o. single dose</description>
        </group>
        <group group_id="E2">
          <title>Ambrisentan at Steady-state</title>
          <description>administration of ambrisentan 5 mg p.o. q.d. on day 3-10</description>
        </group>
        <group group_id="E3">
          <title>Ambrisentan During St John's Wort</title>
          <description>administration of ambrisentan 5 mg p.o. q.d. on day 11-20 and administration of SJW 300 mg p.o. t.i.d. on day 11-20</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>heart palpitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>heat sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>thoracic discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pressure sensation in head</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nightmares</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increase of liver transaminases</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The extent of this interaction was small and thus likely without clinical relevance.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. med. Gerd Mikus</name_or_title>
      <organization>University of Heidelberg</organization>
      <phone>4966215639197</phone>
      <email>gerd.mikus@med.uni-heidelberg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

